Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

NA Rizvi, MD Hellmann, A Snyder, P Kvistborg… - Science, 2015 - science.org
Immune checkpoint inhibitors, which unleash a patient's own T cells to kill tumors, are
revolutionizing cancer treatment. To unravel the genomic determinants of response to this …
被引用次数：8128 相关文章

[引用][C] Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

NA Rizvi, MD Hellmann, A Snyder, P Kvistborg… - Science, 2015 - cir.nii.ac.jp
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer |
CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

NA Rizvi, MD Hellmann, A Snyder… - Science (New York …, 2015 - europepmc.org
Immune checkpoint inhibitors, which unleash a patient's own T cells to kill tumors, are
revolutionizing cancer treatment. To unravel the genomic determinants of response to this …
[HTML] nih.gov

[HTML][HTML] Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

NA Rizvi, MD Hellmann, A Snyder… - Science (New York …, 2015 - ncbi.nlm.nih.gov
Immune checkpoint inhibitors, which unleash a patient's own T cells to kill tumors, are
revolutionizing cancer treatment. To unravel the genomic determinants of response to this …

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

NA Rizvi, MD Hellmann, A Snyder… - … (New York, NY), 2015 - pubmed.ncbi.nlm.nih.gov
Immune checkpoint inhibitors, which unleash a patient's own T cells to kill tumors, are
revolutionizing cancer treatment. To unravel the genomic determinants of response to this …

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

NA Rizvi, MD Hellmann, A Snyder, P Kvistborg… - Science, 2015 - ui.adsabs.harvard.edu
Immune checkpoint inhibitors, which unleash a patient's own T cells to kill tumors, are
revolutionizing cancer treatment. To unravel the genomic determinants of response to this …

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

NA Rizvi, MD Hellmann, A Snyder… - Science (New York …, 2015 - europepmc.org
Immune checkpoint inhibitors, which unleash a patient's own T cells to kill tumors, are
revolutionizing cancer treatment. To unravel the genomic determinants of response to this …